Skip to main content

Advertisement

SpringerLink
Log in

Effect of L-Carnitine Supplementation on Secondary Hyperparathyroidism and Bone Metabolism in Hemodialyzed Patients

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The aim of our work was to test the influence of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients in a randomized study. Eighty-three chronically hemodialyzed patients were observed; 44 were supplemented with L-carnitine (15 mg/kg intravenously after each hemodialysis for 6 months), while 39 took placebo. Levels of free carnitine (CAR), calcium (Ca), inorganic phosphate (P), Ca x P product, parathormone (PTH), bone-specific alkaline phosphatase (b-ALP), osteocalcin (OC), and osteoprotegerin (OPG) were monitored. In comparison with pretreatment values, changes of some selected parameters occurred in the supplemented patients after 6 months (data are expressed as medians; NS, nonsignificant change): PTH, 186.0 vs. 135.5 ng/L (NS); b-ALP, 13.9 vs. 13.2 μg/L (P < 0.05); OC, 78.3 vs. 68.8 μg/L (NS); OPG, 144.0 vs. 182.0 ng/L (P < 0.05). In the controls, there were the following changes: PTH, 148.0 vs. 207.0 ng/L (NS); b-ALP, 15.2 vs. 13.2 μg/L (P < 0.05); OC, 62.7 vs. 79.8 μg/L (P < 0.05); OPG, 140.0 vs. 164.0 ng/L (NS). A significant correlation was found between CAR and OPG changes (r = 0.51, P < 0.001) in the supplemented patients. The supplementation led to a significant increase of serum OPG concentration. Nevertheless, we observed only nonsignificant tendencies to correction of secondary hyperparathyroidism and reduction of bone turnover in hemodialyzed patients supplemented with L-carnitine in contrast to controls. At this point, the use of L-carnitine does not seem to be justified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schonekess BO, Allard MF, Lopaschuk GD (1995) Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77:726–734

    PubMed  CAS  Google Scholar 

  2. Vaz FM, Wanders R (2002) Carnitine homeostasis and human disease: advances in metabolite analysis. LabMedica 19:14–17

    Google Scholar 

  3. Battistella PA, Angelini C, Vergani L, Bertoli M, Lorenzi S (1978) Carnitine deficiency induced during hemodialysis. Lancet 1:939

    Article  PubMed  CAS  Google Scholar 

  4. Bohmer T, Bergrem H, Eiklid K (1978) Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet 1:126–128

    Article  PubMed  CAS  Google Scholar 

  5. Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, Nation RL (2000) Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 68:238–249

    Article  PubMed  CAS  Google Scholar 

  6. Suzuki Y, Nariata M, Yamazaki N (1982) Effects of L-carnitine on arrhythmias during hemodialysis. Jpn Heart J 23:349–359

    PubMed  CAS  Google Scholar 

  7. Goral S (2001) Levocarnitine’s role in the treatment of patients with end-stage renal disease: a review. Dial Transplant 30:530–538

    Google Scholar 

  8. Horl WH (2004) The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Translpant 19(suppl 5):V2–V8

    Article  Google Scholar 

  9. Portale AA, Halloran BP, Morris RC Jr (1989) Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D3 by phosphorus in normal men. J Clin Invest 83:1494–1499

    PubMed  CAS  Google Scholar 

  10. Portale AA, Booth BE, Halloran BP, Morris RC Jr (1984) Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580–1589

    Article  PubMed  CAS  Google Scholar 

  11. Combe C, Aparicio M (1994) Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381–1386

    Article  PubMed  CAS  Google Scholar 

  12. Slatopolsky E, Brown A, Dusso A (2001) Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37(suppl 2):S54–S57

    PubMed  CAS  Google Scholar 

  13. Adamek G, Felix R, Guenther HL, Fleisch H (1987) Fatty acid oxidation in bone tissue and bone cells in culture. Characterization and hormonal influences. Biochem J 248:129–137

    PubMed  CAS  Google Scholar 

  14. Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD (1990) Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912–918

    Article  PubMed  CAS  Google Scholar 

  15. Nakazawa R, Furuhashi S, Shioda T, Kawamura K, Kimura K, Azuma N, Suzuki M (2002) Effect of long-term L-carnitine supplementation on hyperphosphatemic hemodialysis patients [abstract]. Presented at the 11th International Congress on Nutrition and Metabolism in Renal Disease, Nagoya, Japan, March 29–31, 2002

  16. Vesela E, Racek J, Trefil L, Jankových V, Pojer M (2001) Effect of L-carnitine supplementation in hemodialysis patients. Nephron 88:218–223

    Article  PubMed  CAS  Google Scholar 

  17. Khosla S (2001) The OPG/RANKL/RANK system. Endocrinology 142:5050–5055

    Article  PubMed  CAS  Google Scholar 

  18. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618–625

    Article  PubMed  CAS  Google Scholar 

  19. Seim H (1998) Carnitine. In: Lothar T (ed), Clinical Laboratory Diagnostics. TH-Books Verlagsgesellschaft, Frankfurt, 202–207

  20. National Kidney Foundation (2003) Kidney Disease Quality Outcomes Initiative (K/DOQI) clinical practice guidelines. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(suppl 3):S1–S201

    Google Scholar 

  21. Locatelli F (2004) The need for better control of secondary hyperparathyroidism. Nephrol Dial Translpant 19(suppl 5):V15–V19

    Article  Google Scholar 

  22. Guarnieri G, Toigo G, Crapesi L, Situlin R, Del Bianco MA, Corsi M, LoGreco P, Paviotti G, Mioni G, Campanacci L (1987) Carnitine metabolism in chronic renal failure. Kidney Int 32(suppl 22):S116–S127

    Google Scholar 

  23. Urena P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141–2156

    Article  PubMed  CAS  Google Scholar 

  24. Martin KJ, Olgaard K; Bone Turnover Work Group (2004) Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43:558–565

    Article  PubMed  Google Scholar 

  25. Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Arlot M, Chapuy MC, Meunier PJ (1986) Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 63:892–897

    Article  PubMed  CAS  Google Scholar 

  26. Sebert JL, Ruiz JC, Fournier A, Fardellone P, Gueris J, Marie A, Moriniere P, Codet MP, Renaud H (1987) Plasma bone Gla-protein: assessment of its clinical value as an index of bone formation in hemodialyzed patients. Bone Miner 2:21–27

    PubMed  CAS  Google Scholar 

  27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319

    Article  PubMed  CAS  Google Scholar 

  28. Steddon SJ, Fan SL, Cunningham J (2005) New prospects for the management of renal bone disease. Nephron Clin Pract 99:c1–c7

    Article  PubMed  Google Scholar 

  29. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348–360

    Article  PubMed  CAS  Google Scholar 

  30. Nakashima A, Yorioka N, Doi S, Takasugi N, Shigemoto K, Kohno N (2006) Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int 17:841–846

    Article  PubMed  CAS  Google Scholar 

  31. Kazama JJ, Kato H, Sato T, Shigematsu T, Fukagawa M, Iwasaki Y, Gejyo F (2002) Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 17:1860–1861

    Article  PubMed  CAS  Google Scholar 

  32. Avbersek-Luznik I, Malesic I, Rus I, Marc J (2002) Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 40:1019–1023

    Article  PubMed  CAS  Google Scholar 

  33. Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552–3561

    Article  PubMed  CAS  Google Scholar 

  34. Avbersek-Luznik I, Balon BP, Rus I, Marc J (2005) Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 20:566–570

    Article  PubMed  CAS  Google Scholar 

  35. Colucci S, Mori G, Vaira S, Brunetti G, Greco G, Mancini L, Simone GM, Sardelli F, Koverech A, Zallone A, Grano M (2005) L-Carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 76:458–465

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study was supported by the Internal Grant Agency (IGA) grant NB/7350-3 from the Ministry of Health, Czech Republic.

Author information

Authors and Affiliations

  1. Institute of Clinical Biochemistry and Hematology, Charles University Medical Faculty and Faculty Hospital, Alej Svobody 80, CZ-304 60, Pilsen, Czech Republic

    Roman Cibulka, Jaroslav Racek, Daniel Rajdl, Ladislav Trefil & Romana Siroka

  2. 2nd Department of Internal Medicine, Charles University Medical Faculty and Faculty Hospital, Pilsen, Czech Republic

    Richard Pikner

  3. Dialysis Centers EuroCare, Pilsen and Teplice, Czech Republic

    Eugenie Vesela & Marie Studenovska

Authors
  1. Roman Cibulka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaroslav Racek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Pikner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Rajdl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ladislav Trefil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eugenie Vesela
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marie Studenovska
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Romana Siroka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roman Cibulka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cibulka, R., Racek, J., Pikner, R. et al. Effect of L-Carnitine Supplementation on Secondary Hyperparathyroidism and Bone Metabolism in Hemodialyzed Patients. Calcif Tissue Int 81, 99–106 (2007). https://doi.org/10.1007/s00223-007-9041-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-007-9041-1

Keywords

Search

Navigation